About: Corticosteroid administration for viral pneumonia: COVID-19 and beyond

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Corticosteroid administration for viral pneumonia: COVID-19 and beyond Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Corticosteroid administration for viral pneumonia: COVID-19 and beyond
Creator	Yang, Ling Xu, Jin-Fu Yang, Jia-Wei Luo, Rong-Guang
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Corticosteroids are commonly used as adjuvant therapy for acute respiratory distress syndrome (ARDS) by many clinicians due to their perceived anti-inflammatory effects. However, for patients with severe viral pneumonia, the corticosteroid treatment is highly controversial. OBJECTIVES: The purpose of this review is to systematically evaluate the effect and potential mechanism of corticosteroid administration in pandemic viral pneumonia. SOURCES: We comprehensively searched all manuscripts on corticosteroids therapy for influenza, SARS, MERS and SARS-CoV-2 viral pneumonia from the PubMed, EMBASE, Web of Science and Cochrane Library databases. CONTENT: We systematic summarized the effects of corticosteroids therapy for pandemic viral pneumonia and the potential mechanism of corticosteroid worked in COVID-19. IMPLICATIONS: Observational studies showed that corticosteroid treatment was associated with increased mortality and nosocomial infections for influenza and delay virus clearance for SARS-CoV and MERS-CoV. Limited data on corticosteroid therapy for COVID-19 were reported. Corticosteroids were used in about a fifth of patients (670/2995, 22.4%). Although clinical observational studies reported the improvement in symptoms and oxygenation for the severe COVID-19 patients received corticosteroids therapy, case fatality rate in the corticosteroid group was significantly higher than that in the non-corticosteroid group (69/443, 15.6% vs 56/1310, 4.3%). Compared with non-severe patients, severe patients were more likely to receive corticosteroid therapy (201/382, 52.6% vs 201/1310, 15.3%). Although there is no evidence of corticosteroid therapy reduce the mortality of COVID-19 patients, some improvements in clinical symptoms and oxygenation were reported in some clinical observational studies. Excessive inflammatory response and lymphopenia might be critical factors associated with disease severity and mortality of COVID-19. Sufficiently powered randomized controlled trials with rigorous inclusion/exclusion criteria and standardized dose and duration of corticosteroids are needed to verify the effectiveness and safety of corticosteroid therapy.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2020.06.020
bibo:pmid	32603802
has license	no-cc
sha1sum (hex)	ce0061e2c4f56b3c1f905f5c79a33c2622f0ff18
schema:url	https://doi.org/10.1016/j.cmi.2020.06.020
resource representing a document's title	Corticosteroid administration for viral pneumonia: COVID-19 and beyond
has PubMed Central identifier	PMC7320691
has PubMed identifier	32603802
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:ce0061e2c4f56b3c1f905f5c79a33c2622f0ff18#body_text
is schema:about of	named entity 'influenza' named entity 'superinfection' named entity 'MERS-CoV' named entity 'indications' named entity 'Title' named entity 'Corticosteroid' named entity 'HAZARD RATIO' named entity 'ASSOCIATED WITH' named entity 'controlled' named entity 'corticosteroid' named entity 'Corticosteroids' named entity 'Keywords' named entity 'SARS-CoV' named entity 'influenza' named entity 'hazard ratio' named entity 'SARS-CoV' named entity 'corticosteroid' named entity 'Corticosteroids' named entity 'COVID-19' named entity 'Asian' named entity 'Singapore' named entity 'influenza' named entity 'influenza' named entity 'Corticosteroid' named entity 'data' named entity '1.08' named entity 'MERS' named entity 'propensity score matching' named entity 'corticosteroid therapy' named entity 'corticosteroid' named entity 'regression analysis' named entity 'viral pneumonia' named entity 'pneumonia' named entity 'methylprednisolone' named entity 'corticosteroid' named entity 'adjuvant therapy' named entity 'corticosteroid' named entity 'COVID' named entity 'methylprednisolone' named entity 'COVID-19' named entity 'MERS' named entity 'Interquartile range' named entity 'corticosteroids' named entity 'influenza' named entity 'influenza' named entity 'IQR' named entity 'corticosteroid' named entity 'Corticosteroids' named entity 'IQR' named entity 'respiratory distress syndrome' named entity 'SARS' named entity 'anti-inflammatory' named entity 'ARDS' named entity 'corticosteroid' named entity 'data processing' named entity 'corticosteroid' named entity '2019-nCoV' named entity 'SARS' named entity 'coronavirus' named entity 'corticosteroid therapy' named entity 'corticosteroid' named entity 'ICU' named entity 'corticosteroids' named entity 'COVID-19' named entity 'SARS-CoV' named entity 'viral pneumonia' named entity 'Observational studies' named entity 'MERS-CoV' named entity 'corticosteroid' named entity 'virus' named entity 'SARS-COV' named entity 'corticosteroid' named entity 'COVID' named entity 'Beijing' named entity 'confidence interval' named entity 'nosocomial infections' named entity 'superinfection' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software